MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional gene expression regulators. The expression profiling of miRNAs has already entered into cancer clinics as diagnostic and prognostic biomarkers to assess tumor initiation, progression and response to treatment in cancer patients.
Several studies reported that miR-92a, miR-143 and miR-342 were dysregulated in different AML cell lines and tumor samples (14) (15) (16) (17) . Thus, studying the expression profile of these miRNAs in plasma presents new non-invasive biomarkers for this type of hematologic malignancy. In the present study, we examined alterations in the expression of miR-92a, miR-143 and miR-342 in plasma samples from AML patients and healthy volunteers to determine the significance of these miRNAs as diagnostic tools for AML. We also analyzed the correlation between the expression of these miRNAs and the clinicopathological features of AML.
Materials and methods

Patients and samples
The present study was conducted on 65 plasma samples provided by AML patients, who Table 1 . Blood (10 ml) was drawn on Ethylene diamine tetra acetic acid (EDTA) from an antecubital vein in AML patients or healthy control subjects using standard percutaneous venipuncture. Plasma was separated by centrifugation at 3000 rpm for 10 min at 4 °C, and then recentrifuged at 5000 rpm for 5 min to obtain cell-free plasma, which was stored at −80 C until use. Only non-hemolyzed plasma samples were used in our study, as haemolysis affects miRNA levels. Hemolysis was detected by spectral analysis at 541 nm (19, 20) .
Plasma miRNA assay
Total RNA with preserved miRNAs was 
Statistical analysis
Comparisons of quantitative variables were performed using the nonparametric Mann-Whitney U test when comparing AML group and control group. The P-values less than 0.05 were considered as statistically significant. Statistical comparison among AML subgroups was performed by one-way analysis of variance (Anova). When a significant overall p value (P<0.05) was present, differences between individual means were tested using
Fisher's least-significant differences (LSD).
Spearman's rank correlation coefficient was also performed to find the correlations between the expression of miRNAs and other variables, e.g. age,
gender, and FAB classification. Receiver operator characteristic (ROC) curves were derived and areaunder-the curve (AUC) analysis was performed to obtain the best cut-off value of miRNA value for detecting AML patients. All statistical analyses were performed using SPSS 23 software, and graphs were generated using MedCalc Version
(MedCalc statistical software).
Results
Expression levels of miRNAs
The data presented in Figure 1 shows that there is a significant decrease in the expression levels of miR-92a, miR-143 and miR-342 in AML patients compared with the control group (P< 0.001). The ratios of the plasma miRNAs in AML patients to healthy controls are displayed in Table 2 with their statistical significance. In the present study, there was no significant difference in the expression of the three miRNAs among AML subtypes (M0, M1, M2, M4, and M5). However, all AML subtypes showed significant decrease in the three miRNAs expression levels compared to healthy normal subjects ( Figure 2 ). As only one AML case with M7 classification was recruited, therefore, group M7 was not included in the post hoc tests because there was a standard deviation of this group.
In addition, no significant correlations were found between the expression levels of any of the three miRNAs and age, gender, and FAB classification in AML patients, except for miR-92a.
As shown in Table 3 , only miR-92a showed a significant correlation (r=.397, P= 0.01) with FAB classification.
Diagnostic performance of miR-92a, miR-143 and miR-342 for AML
The diagnostic performance of miR-92a, miR-143 and miR-342 (and a combination of these markers) in differentiating AML patients from In conclusion, this study shows a reduction in miR-92a, miR-143 and miR-342 levels in plasma of AML patients. The combination of the plasma markers miR-92a, miR-143 and miR-342 represents a very promising screening test for AML diagnosis.
Although testing with these markers reached high sensitivity and specificity for AML prediction,
there is a need to compare the results with other types of cancer to clarify whether these miRNAs are useful as specific markers for AML.
